GlassScriptPhysician profile
Arun Chandrakantan
NPI 1346206760
$2,947.85
in general payments reported to CMS, 2019-2025
28 companies · $695 in 2025
The $695 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $139 · 2021: $896 · 2022: $485 · 2023: $311 · 2024: $422 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908 · Consulting Fee: $500 · Education: $20.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.00 |
| Consulting Fee | $500.00 |
| Education | $20.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $1,091.67 | 2021-2025 | |
| Amgen INC. | $313.79 | 2024-2025 | Krystexxa, Tavneos |
| C. R. Bard, INC. & Subsidiaries | $290.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $253.24 | 2020-2024 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $164.55 | 2021-2023 | Krystexxa |
| Merck Sharp & Dohme LLC | $160.77 | 2023-2025 | Prevymis |
| Veloxis Pharmaceuticals, INC. | $118.23 | 2020-2025 | Envarsus |
| Mallinckrodt Hospital Products INC. | $72.74 | 2021-2022 | |
| Eurofins Viracor, LLC | $68.33 | 2024 | |
| Novartis Pharmaceuticals Corporation | $44.97 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $39.47 | 2020-2024 | Rayaldee |
| Fresenius USA Marketing, INC. | $33.90 | 2023-2024 | |
| Amarin Pharma, INC. | $33.03 | 2021 | |
| Alexion Pharmaceuticals, INC. | $30.68 | 2022-2024 | Ultomiris |
| Novo Nordisk INC | $30.03 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $26.86 | 2020 | |
| Abbott Laboratories | $22.15 | 2023 | Freestyle Libre 3 |
| Pfizer INC. | $20.24 | 2023 | |
| Vifor Pharma, INC. | $18.39 | 2023 | Veltassa |
| Sanofi-Aventis U.S. LLC | $16.20 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.68 | 2021 | |
| Nxstage Medical, INC. | $15.48 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.27 | 2021 | |
| Becton, Dickinson and Company | $14.16 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.19 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.90 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.54 | 2020 | |
| Travere Therapeutics, INC. | $0.39 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Chandrakantan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.